Morphosys Ag (MOR – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today. The company’s shares opened today at $17.51.
Butler covers the Healthcare sector, focusing on stocks such as Morphosys Ag, Athira Pharma, and Cormedix. According to TipRanks, Butler has an average return of -4.9% and a 39.48% success rate on recommended stocks.
In addition to JMP Securities, Morphosys Ag also received a Hold from Citi’s Vineet Agrawal in a report issued today. However, yesterday, Wells Fargo maintained a Buy rating on Morphosys Ag (NASDAQ: MOR).
See today’s best-performing stocks on TipRanks >>
MOR market cap is currently $1.7B and has a P/E ratio of 30.34.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Morphosys Ag (MOR) Company Description:
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Read More on MOR:
